Natco Pharma Ltd Q3 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Published 3 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹16.4K Cr

Anticipated revenue for fiscal 2026 is around INR 4,300 crores, based on Q3 and Q4 projections (Page 12). For fiscal year 2026, Natco expects revenue around INR 4,300 crores and PAT between INR 1,280-1,300 crores (Page 12). - Emerging markets, including Brazil and Middle East, along with Adcock profit consolidation, are anticipated to drive future growth (Page 17). - The U.S.

From Natco Pharma Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Price

₹882

Market Cap

₹16.4K Cr

P/E Ratio

11.6

How does Natco Pharma Ltd rank in Pharmaceuticals & Biotechnology?

Compare Natco Pharma Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Natco Pharma Ltd — Quarterly revenue & net profit

Revenue Net Profit

Sep 2024

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Reported quarterly figures (₹ Cr). Latest: revenue ₹647 Cr, net profit ₹151 Cr.

Full financials →

📊 Revenue & Sales Performance

→Anticipated revenue for fiscal 2026 is around INR 4,300 crores, based on Q3 and Q4 projections (Page 12).
→Emerging markets (Middle East, Brazil) and Adcock profit consolidation expected to drive growth in export revenue (Page 17).
→Domestic Indian market expected to grow over 20% in the next year, driven primarily by semaglutide (Page 12).
→U.S. market: Several ANDA approvals and product launches, including first-to-file/shared first-to-file, expected in the next 12 months, contributing to growth (Page 16).
→Base business expected to stabilize in H2 FY26; new product launches will increment growth (Page 16).
→Management confident of comfortable growth over next couple of years (Page 17).
→Long-term aspiration to reach ~INR 10,000 crores turnover, largely through M&A and geographic expansion (Page 10).

📈 Profitability & Margins

→For fiscal year 2026, Natco expects revenue around INR 4,300 crores and PAT between INR 1,280-1,300 crores (Page 12).
→Emerging markets, including Brazil and Middle East, along with Adcock profit consolidation, are anticipated to drive future growth (Page 17).
→The U.S. market is expected to see strong launches supporting growth in fiscal 2027 (Page 17).
→Domestic growth in India is projected to exceed 20% mainly driven by semaglutide (Page 12).
→The company maintains confidence in comfortable growth over the next couple of years, with detailed guidance expected in the May call after audited numbers (Page 17).
→R&D expenditure remains prioritized for complex generics, supporting future pipeline-driven growth (Page 6).
→M&A activity, especially outside India, is targeted to supplement organic growth and accelerate scale (Page 10, 17-18).

See what Natco Pharma Ltd said on profitability & margins — free account, 30 seconds.

🏗️ Capital Expenditure Plans

→No explicit current capital expenditure or strategic investment details were disclosed in the call.
→The company is actively pursuing 2-3 acquisition targets, focusing on emerging markets and established brand businesses to supplement portfolio growth.
→Rajeev Nannapaneni mentioned a preference for acquisitions outside India due to better returns despite currency and political risks.
→They currently have enough cash (approx. INR2,500 crores net) post Adcock acquisition and prefer preserving cash for large acquisitions rather than buybacks.
→Financing for large acquisitions may be a mix of cash, debt, and equity depending on the size and circumstances.
→There is no plan to raise capital immediately, but fundraising could be considered if a large acquisition opportunity arises.
→No specific capex plans for manufacturing were detailed; FDA plant statuses were updated but no fresh investments mentioned.

💰 Fundraising & Capital Structure

- Currently, Natco Pharma does not plan to raise any capital through debt or equity as they have sufficient cash reserves. - The management is not a big fan of debt but will make judgment calls closer to the time if acquisition opportunities arise. - For large acquisitions, the company may consider a mix of cash, debt, and equity financing. - Presently, no capital raising is planned, but if a large transaction occurs, Natco Pharma is open to changing this stance. - The focus is on preserving cash for potential large acquisitions similar to Adcock Ingram. - Actively pursuing 2-3 acquisition targets with hopes to close at least 1 or 2 deals in 2025 or 2026, subject to clearances. (Source: Page 10 and Page 11 of the transcript)

See what Natco Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.

📋 Order Book & Pipeline

The transcript does not provide explicit details on the current or expected order book/pending orders. However, key related points include: - The company expects strong growth in the U.S. market with several ANDA approvals and product launches expected in the next 12 months, including a shared First-to-File (FTF) launch. - Emerging markets like Brazil and Middle East are showing good product launches and approvals, expected to drive export revenue growth. - Domestic market growth is largely driven by semaglutide, with a 20%+ growth target in India. - Multiple Para IV litigations and patent challenges are ongoing, impacting timelines for specific product launches. - The company is actively pursuing 2-3 large M&A targets to supplement its portfolio and geographical expansion. - R&D filings include 4-5 products this year, with 8 expected in total. No explicit order book size or pending order value was shared during the call.

Key Metrics

What Natco Pharma's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

OneSource Specialty Pharma Ltd (Q3 FY26)
OneSource Specialty Pharma is aggressively investing in capacity expansion with over INR 700 crores (approximately $100 million) planned for flagship site…
Mankind Pharma Ltd (Q3 FY26)
Overall domestic prescription business growth for Q3 was 9%+ and 8.2% for 9 months (excluding OTC), indicating steady growth. Key concall takeaways from…
Gland Pharma (Q3 FY26)
Investments of INR 2,000 crores over next 5 years, including Brownfield expansions, BFS lines, and ophthalmic lines, to enhance capacity and drive volume/value…
Shilpa Medicare Ltd (Q3 FY26)
Formulation business growing robustly, with 104% quarter-on-quarter growth excluding licensing income. Key concall takeaways from Shilpa Medicare's Q3 FY26…

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Natco Pharma Ltd Q3 FY26 results?

What is Natco Pharma Ltd share price analysis?

Natco Pharma Ltd currently shows a neutral. The stock trades at a P/E of 11.6 with a market cap of ₹16,434 Cr. Investors should review the full earnings analysis for detailed insights.

Is Natco Pharma Ltd planning capital expenditure?

No explicit current capital expenditure or strategic investment details were disclosed in the call. - The company is actively pursuing 2-3 acquisition targets, focusing on emerging markets and established brand businesses to supplement portfolio growth. - Rajeev Nannapaneni mentioned a preference for acquisitions outside India due to better returns despite currency and political risks. - They currently have enough cash (approx.

Keep Natco Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.